hat
Ki ka geri ou espesifik ki itilize a, peut être envisagé? Pou Lovell-plak pa gen anpil. -Implantation diagnostic enetik (PGD) -nbriyon elijib pou yo chwazi moun ki pa pote kèk maladi risk-se deja nan sèvi ak yon lis lontan enetik kondisyon, jèn BRCA1 a, li pwen yo. Men, li qu' Crispr te kapab gen yon kote lè miltip embryons sont afekte, ces tankou ka a, moun ki pa ka fè pitit ou bon venn tè sib poutèt mutations sou womozòm Y a. Tout gason embryons (te pwodwi pa FIV) ap gen mutation tou sa.
eng
What specific therapeutic uses might be envisaged? For Lovell-Badge there aren’t many. Pre-implantation genetic diagnosis (PGD) – embryo screening to select those that don’t carry certain disease risks – is already in use for a long list of genetic conditions including the BRCA1 gene, he points out. But he concedes Crispr could have a place when multiple embryos are affected, such as in the case of men who are infertile or sub-fertile because of mutations on the Y chromosome. Any male embryos (produced by IVF) will also have that same mutation.